Suggested remit: To appraise the clinical and cost effectiveness of abaloparatide within its marketing authorisation for treating osteoporosis in postmenopausal women.
 
Status In progress
Technology type Medicine
Decision Selected
Process STA Standard
ID number 882

Project Team

Project lead Leena Issa

Email enquiries

External Assessment Group School of Health and Related Research (ScHARR), University of Sheffield

Timeline

Key events during the development of the guidance:

Date Update
27 July 2023 Invitation to participate
23 March 2023 Following the changes to remove technical engagement as standard from appraisal timelines, the timelines for the appraisal of Abaloparatide for treating osteoporosis in postmenopausal women have been revised. It is anticipated that the appraisal will begin in mid-July 2023 when we will write to you about how you can get involved.
25 January 2023 - 22 February 2023 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 882
25 January 2023 In progress. Scoping commencing
17 June 2016 Suspended. For information abaloparatide will be appraised alongside raloxifene, teriparatide, denosumab and strontium ranelate [ID901] as a Multiple Technology Appraisal (MTA). Further details regarding the timings of this MTA will be available in due course.
17 June 2016 Draft scope documents

For further information on our processes and methods, please see our CHTE processes and methods manual